Context: The Indian Council of Medical Research (ICMR) is seeking to develop a pediatric oral formulation of hydroxyurea to treat sickle cell disease in India, where over 20 million individuals are affected.
Currently, hydroxyurea is mainly available in 500 mg capsules or 200 mg tablets, making dosing for children challenging.
This initiative is crucial, especially with the launch of the National Mission to eliminate Sickle Cell Anemia/SCD by 2047.
What is SCD (Sickle Cell Disease)?
Sickle Cell Disease (SCD) is a genetic disorder that affects the shape of red blood cells, causing them to become sickle-shaped instead of round. This abnormal shape can lead to various complications, including pain, anemia, and organ damage. SCD is one of the most common inherited blood disorders and can result in serious health issues, including stroke and organ failure.
Source: Th
